Immunization of disease-free melanoma patients with different HLA-A2 peptides.

Trial Profile

Immunization of disease-free melanoma patients with different HLA-A2 peptides.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2013

At a glance

  • Drugs IMP 321 (Primary) ; IMP 321 (Primary) ; Melanoma vaccine (Primary) ; Melanoma vaccine (Primary) ; Montanide ISA-51; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 14 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top